Launched the commercialization of long, complex oligos through our Fully Enzymatic Synthesis (FES) technology and established technology roadmaps to continue the advancement of synthesis performance and capacity growth, overseeing R&D efforts and manufacturing transfer. Our offerings fills the frustrating gap of getting DNA at the sequence complexity, length and purity for cutting edge applications in CRISPR gene editing and protein engineering.Successfully completed key milestone and awarded an addition $4M for a DARPA-funded collaboration with GE Healthcare. The DARPA NOW program aims to develop a rapidly scalable and deployable mobile vaccine production platform used for pandemic-response countermeasures.

Delivered a breakthrough DNA synthesis manufacturing platform and enzymatic synthesis process for commercial readiness by leading a team of cross-functional engineers, biochemists, and molecular biologists. Launched into early commercialization through an early access program delivering unprecedented long, complex oligo offering.

Led the integrated cartridge development for the NextSeq 1000/2000 platform (launched in 2020), delivering an affordable, completely self-contained, disposable yet highly recyclable cartridge for up to 1.1B reads in a single run. Served as the functional manager for the Fluidics Engineering group, providing specialized microfluidic expertise across all sequencing platforms.

Led the fluidics architecture/design for the NextSeq 500 platform (launched in 2014), the first desktop platform to sequence a human genome in a single run, delivering high-throughput capable to researchers. Served as functional lead of the Fluidics Engineering group, expanding Illumina's capabilities to drive toward faster and less expensive architectures.

Fluidics architect lead of the NextSeq 500 sequencing platform (launched in 2014), with the opportunity to work with product managers and marketing for product definition and capability.

Established the company's engineering team and led the development of RapidPlex®, a $21M DHS funded effort for the rapid, autonomous detection of biothreats in aerosol and water samples in under 30 minutes.

Redefined platform technologies to demonstrate feasibility of a rapid, parallel PCR and antibody-based assay in under 30 minutes.

Founding member of a Duke University spinout focused on delivering rapid point-of-care diagnostic tests using a groundbreak solid-state microfluidic technology called digital fluidics. The company was acquired in 2013 by Illumina.